NO20031939L - Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler - Google Patents

Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler

Info

Publication number
NO20031939L
NO20031939L NO20031939A NO20031939A NO20031939L NO 20031939 L NO20031939 L NO 20031939L NO 20031939 A NO20031939 A NO 20031939A NO 20031939 A NO20031939 A NO 20031939A NO 20031939 L NO20031939 L NO 20031939L
Authority
NO
Norway
Prior art keywords
diaminocyclohexyl
purines
disubstituted
acyl
trans
Prior art date
Application number
NO20031939A
Other languages
English (en)
Other versions
NO20031939D0 (no
Inventor
David Roger Borcherding
Jennifer Ann Dumont
Norton P Peet
Paul S Wright
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0117075.2A external-priority patent/GB0117075D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20031939D0 publication Critical patent/NO20031939D0/no
Publication of NO20031939L publication Critical patent/NO20031939L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20031939A 2000-10-31 2003-04-29 Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler NO20031939L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24456700P 2000-10-31 2000-10-31
GBGB0117075.2A GB0117075D0 (en) 2000-10-31 2001-07-13 Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents
PCT/US2001/044835 WO2002042303A2 (en) 2000-10-31 2001-10-31 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents

Publications (2)

Publication Number Publication Date
NO20031939D0 NO20031939D0 (no) 2003-04-29
NO20031939L true NO20031939L (no) 2003-06-19

Family

ID=26246308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031939A NO20031939L (no) 2000-10-31 2003-04-29 Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler

Country Status (14)

Country Link
EP (1) EP1377579B1 (no)
JP (1) JP4348081B2 (no)
AT (1) ATE426603T1 (no)
AU (2) AU3938802A (no)
BR (1) BR0115080A (no)
CA (1) CA2427338C (no)
DE (1) DE60138140D1 (no)
DK (1) DK1377579T3 (no)
ES (1) ES2324763T3 (no)
IL (1) IL155590A0 (no)
MX (1) MXPA03003774A (no)
NO (1) NO20031939L (no)
NZ (1) NZ525264A (no)
WO (1) WO2002042303A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
EP1636207A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
ATE531372T1 (de) * 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) * 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) * 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100568658B1 (ko) * 1998-02-26 2006-04-07 아벤티스 파마슈티칼스 인크 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2001044260A2 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof

Also Published As

Publication number Publication date
WO2002042303A2 (en) 2002-05-30
NZ525264A (en) 2005-12-23
WO2002042303A3 (en) 2003-10-30
JP4348081B2 (ja) 2009-10-21
NO20031939D0 (no) 2003-04-29
ATE426603T1 (de) 2009-04-15
JP2004517075A (ja) 2004-06-10
CA2427338A1 (en) 2002-05-30
ES2324763T3 (es) 2009-08-14
AU2002239388B2 (en) 2006-05-25
BR0115080A (pt) 2003-09-23
EP1377579A2 (en) 2004-01-07
DE60138140D1 (de) 2009-05-07
AU3938802A (en) 2002-06-03
DK1377579T3 (da) 2009-08-31
MXPA03003774A (es) 2003-07-28
CA2427338C (en) 2008-06-10
IL155590A0 (en) 2003-11-23
EP1377579B1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20031939D0 (no) Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4- diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler
NO331175B1 (no) Kinazolin-derivater som angiogenese-inhibitorer og mellomprodukter derav.
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
DK1254899T3 (da) Piperazinderivater og deres anvendelse som anti-inflammatoriske midler
IT1309590B1 (it) Derivati di 1-alcossi-polialchil-piperidine e loro impiego comeregolatori della polimerizzazione.
ITRM20010356A0 (it) "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
MA25836A1 (fr) Derives de pyridine avec une activite inhibitrice de ikb-kinase (ikk-b)
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
ATE332903T1 (de) Kondensierte pyridoindolderivate
NO20032388D0 (no) Salter av et isotiazol-4-karboksamid og anvendelse derav som anti-hyperproliferasjonsmidler
DK0625987T3 (da) Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
ATE346067T1 (de) Carbolinderivate
DK1073416T3 (da) Anvendelse af NO som anti-inflammatorisk middel
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
BR0308170A (pt) Composição para limpeza lìquida aquosa, método para limpeza de um substrato, e, uso de um polioxometalato
NO20021007D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-oner og deres anvendelse som lipasehemmere
NO20030998D0 (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ATE246690T1 (de) Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application